New Mechanism Discovered for Lethal Pediatric Brain Tumor

International Research Team Uncovers Role of Male Hormones in PFA Ependymoma Growth

An international research team has identified the mechanism driving the growth of Posterior Fossa Type A (PFA) ependymoma, a lethal pediatric brain tumor. The team includes researchers from Baylor College of Medicine, Texas Children's Hospital, McGill University, and the University of Pittsburgh School of Medicine.

Published in Nature, their findings indicate that androgens, commonly known as male hormones, promote the growth of PFA ependymomas.

"Crucially, studies showed that inhibiting androgen signaling leads to a reduction in tumor cell proliferation."

This discovery suggests a novel therapeutic strategy for this childhood cancer, which currently lacks effective treatments.

Addressing a Treatment Gap

Previously, the drivers of PFA ependymoma growth were unclear, as the tumor lacked distinct genetic markers typically used to develop therapies. The research approached the problem by examining other factors.

Prior observations indicated that most PFA ependymoma patients are male and exhibit lower survival rates than females. The mechanisms underlying these sex differences were previously unknown. Additionally, female brain cells appear more developed than male cells at similar early developmental stages.

Hormones, Not Chromosomes, Drive Growth

Investigators explored whether sex differences in susceptibility were linked to sex chromosomes or sex hormones.

Through studies on animal models and cancer cells, they determined that androgens maintain PFA ependymoma cells in a less-developed, growth-prone state.

No differences were attributed to chromosomal factors, and female sex hormones did not alter PFA cell growth compared to controls.

Promising New Therapeutic Direction

This research provides a biological explanation for the recognized sex differences in PFA ependymoma. The findings highlight a link between early hormone exposure and tumor formation, suggesting that anti-androgen therapies could be a promising treatment direction for this disease.